Roche Holding AG Part. Cert.

Roche Holding is a healthcare company. Co. operates in two Divisions, Pharmaceuticals and Diagnostics. Co.'s pharmaceuticals division is comprised of two business segments Roche Pharmaceuticals and Chugai. Co.'s pharmaceuticals division provides therapies including Cotellic, in combination with Zelboraf for advanced melanoma, and Alecensa for a specific type of lung cancer. Co.'s diagnostics division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. Co.'s diagnostics division provides in vitro diagnostic tests, used by healthcare providers to screen, diagnose and monitor therapies.
  • TickerROG
  • ISINCH0012032048
  • ExchangeSix Swiss Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountrySwitzerland

Analysts

Jean-Christophe Dourret

Roche Holding : Roche - 15 Jul 2019

...

Jean-Christophe Dourret

Roche Holding : Roche - 15 juill 2019

...

Karen Andersen

Morningstar | Rebate Rule Is Dead: Supply Chain Benefits, Drug Firms Pressured

First reported July 10 by Axios, the Trump administration is not planning to finalize the proposed rule altering the flow of drug rebates purchased through Medicare Part D plans. The rule would have changed the business model of pharmacy benefit managers, requiring any negotiated discounts to be passed directly to the beneficiary at the point of sale rather than used as a mechanism to lower the costs to the insurance plan overall. While this led to a rally for PBMs/insurers and distributors, drug stocks sank as investors wondered where President Donald Trump's focus will turn next. Taking reba...

Karen Andersen

Rebate Rule Is Dead: Supply Chain Benefits, Drug Firms Pressured

First reported July 10 by Axios, the Trump administration is not planning to finalize the proposed rule altering the flow of drug rebates purchased through Medicare Part D plans. The rule would have changed the business model of pharmacy benefit managers, requiring any negotiated discounts to be passed directly to the beneficiary at the point of sale rather than used as a mechanism to lower the costs to the insurance plan overall. While this led to a rally for PBMs/insurers and distributors, dru...

Eric Le Berrigaud

SECTOR | Pharmaceuticals | BG OncoDay 2019: clear upside in early-stage NSCLC

SECTOR | Pharmaceuticals | BG OncoDay 2019: clear upside in early-stage NSCLC At our Annual Oncology Day this year, two KOLs (i) summarized the key learnings from ASCO 2019 and (ii) focused specifically on the advances in lung cancer. Then, out of the five companies presenting, three did so in plenary sessions, and we report here the main messages they conveyed

Jean-Jacques Le Fur

Roche: Positive OS for Tecentriq in ES-SCLC (IMpower 133) after the disappointment in NSCLC

Brief Comment - Roche: (NEUTRAL, Fair Value CHF266 (+14%)) Positive OS for Tecentriq in ES-SCLC (IMpower 133) after the disappointment in NSCLC

Roche Holding AG - December 2018 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Roche Holding AG: $4.8 billion acquisition of Spark will have limited impact on credit metrics, but does not come without risks

Credit implications of Roche's acquisition of Spark Therapeutics

Roche Holding AG: Update to credit analysis

Our credit view of Roche Holding AG, reflecting its very strong financial profile, driven by sales growth from new products, which will offset a large upcoming patent cliff.

Roche Holding AG - June 2018 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Roche Holding AG: Update to discussion of key credit factors

Our credit view of Roche reflects a very strong financial profile and pharmaceutical pipeline offsetting a large upcoming patent cliff.

Jean-Christophe Dourret

Roche Holding : Roche - 15 Jul 2019

...

Jean-Christophe Dourret

Roche Holding : Roche - 15 juill 2019

...

Karen Andersen

Morningstar | Rebate Rule Is Dead: Supply Chain Benefits, Drug Firms Pressured

First reported July 10 by Axios, the Trump administration is not planning to finalize the proposed rule altering the flow of drug rebates purchased through Medicare Part D plans. The rule would have changed the business model of pharmacy benefit managers, requiring any negotiated discounts to be passed directly to the beneficiary at the point of sale rather than used as a mechanism to lower the costs to the insurance plan overall. While this led to a rally for PBMs/insurers and distributors, drug stocks sank as investors wondered where President Donald Trump's focus will turn next. Taking reba...

Karen Andersen

Rebate Rule Is Dead: Supply Chain Benefits, Drug Firms Pressured

First reported July 10 by Axios, the Trump administration is not planning to finalize the proposed rule altering the flow of drug rebates purchased through Medicare Part D plans. The rule would have changed the business model of pharmacy benefit managers, requiring any negotiated discounts to be passed directly to the beneficiary at the point of sale rather than used as a mechanism to lower the costs to the insurance plan overall. While this led to a rally for PBMs/insurers and distributors, dru...

Eric Le Berrigaud ...
  • Gary Waanders
  • Hugo Solvet
  • Jean-Jacques Le Fur
  • Ross Blair
  • Victor Floc’h

Top Picks for Q3 2019: Roche stays; DBV and Novartis jump in

Looking back at Q2 2019 What to expect for Q3 2019 Our selection for Q3 2019: one confirmation, two come-backs

François Maury ...
  • Georges Dieng
  • Team Pharma

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 06/28/2019

...

François Maury ...
  • Georges Dieng
  • Team Pharma

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 28/06/2019

...

Alain William ...
  • Alfred Glaser
  • Delphine Brault
  • Martial Descoutures
  • Pierre Corby
  • Pierre Tegner
  • Roland Pfaender
  • Stephane Houri

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 04/17/2019

The M&A option that KBC is considering in Hungary is, in our view, illuminating as regards the M&A/dividend possibilities offered by a portion of the capital. Our estimates show that this scenario is of limited benefit to the shareholder and bear out our Neutral recommendation on the stock (unchanged target price of € 75.0). Cf. report published today. - ...

Alain William ...
  • Alfred Glaser
  • Delphine Brault
  • Martial Descoutures
  • Pierre Corby
  • Pierre Tegner
  • Roland Pfaender
  • Stephane Houri

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 17/04/2019

La piste M&A envisagée par KBC en Hongrie apporte selon nous un éclairage intéressant sur l’optionalité M&A/dividende sur une partie du capital. Nos estimations en démontrent in fine les limites de son intérêt pour l’actionnaire et nous confortent dans notre opinion Neutre sur le titre (OC inchangé à 75.0 €). Cf. étude publiée ce jour. - ...

Alexandre Iatrides ...
  • Alfred Glaser
  • Bruno Cavalier
  • Delphine Brault
  • Emira Sagaama
  • François Maury
  • Georges Dieng
  • Johanna Jourdain
  • Laurence Hofmann
  • Martial Descoutures
  • Matthias Desmarais
  • Olfa Taamallah
  • Pierre Corby
  • Sven Edelfelt
  • Sylvain Goyon
  • Virginie Rousseau
  • Yan Derocles

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 02/25/2019

Equities’ disconnect from the "pessimism" of the bond markets is obvious. The simultaneous choice of cyclicals and protection themes (growth/quality) is disturbing. What should we do when our annual objectives are being met? Avoid succumbing to the cyclical temptation, buy quality by avoiding overpaying the protection criterion linked exclusively to a healthy balance sheet structure. We present the results of a screening combining balance sheet and ROCE trends, which highlights five s...

With a more favourable environment, ROCHE HOLDING AG improves to Positive

ROCHE HOLDING AG (CH), a company active in the Pharmaceuticals industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 4 out of 4 stars, as well as its unchanged, defensive market behaviour. The title leverages a more favourable environment and raises its general evaluation to Positive. As of the analysis date June 21, 2019, the closing price was CHF 277.15 and its potential was estimated at CHF 291.01.

Nurhayati Wan

Roche Holdings

Nurhayati Wan

Roche Holdings

Nurhayati Wan

Roche Holdings

Nurhayati Wan

Roche Holdings

Eric Le Berrigaud

SECTOR | Pharmaceuticals | BG OncoDay 2019: clear upside in early-stage NSCLC

SECTOR | Pharmaceuticals | BG OncoDay 2019: clear upside in early-stage NSCLC At our Annual Oncology Day this year, two KOLs (i) summarized the key learnings from ASCO 2019 and (ii) focused specifically on the advances in lung cancer. Then, out of the five companies presenting, three did so in plenary sessions, and we report here the main messages they conveyed

Eric Le Berrigaud

ROCHE: “We are fine with the show-me mode investors are imposing us” (CFO) - Feedback | BUY - Top Picks | CHF329(+25%)

ROCHE - BUY - Top Picks | CHF329(+25%) “We are fine with the show-me mode investors are imposing us” (CFO) - Feedback 2019 is PoC for management's high degree of reliability 2020 does not look worse (at all) Upside beyond 2020 Where the consensus stands makes no nsense

Eric Le Berrigaud ...
  • Gary Waanders
  • Hugo Solvet
  • Jean-Jacques Le Fur
  • Ross Blair
  • Victor Floc’h

Healthcare: Top Picks Q2 2019: Alcon, Innate, Ipsen and Roche

Healthcare Top Picks Q2 2019: Alcon, Innate, Ipsen and Roche Looking back to Q1 2019 What to expect for Q2 2019

Eric Le Berrigaud

Pharmaceuticals | ESMO 2018: Sequencing Was the Key Word

We synthesise here the main take-away messages from the annual ESMO congress which took place in Munich in October. We present the conclusions in sections organised by organ with three main parts: renal-cell carcinoma (RCC), breast cancer (BC) and lung cancer (NSCLC) with non-uniform levels of innovation and progress. The last section is dedicated to head & neck cancer with encouraging updated data on monatuximab/cetuxima

Roche Holding – Proxinvest Corporate Governance Rating ® : C

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

Expert Corporate Governance Service (ECGS)

Roche - March, 05th 2019

ITEMS 2.1, 2.2, 7 and 8 - Binding votes on the remuneration of the board of directors  and the executive management. Ethos has the following concerns over the amounts requested:  The annual bonuses that will effectively be paid out to the chairman and the CEO are significantly higher than the amounts requested at the general meeting. The remuneration of the non-executive chairman is significantly higher than that of the peer group and includes an annual bonus. For the executive management, the remuneration is significantly higher than that of the peer group and the remuneration structure is n...

Valérie GASTALDY

Analyse court terme - ROCHE HOLDING AG : Les cours progressent encore.

La tendance de fond est clairement orientée à la hausse. Les cours progressent encore, mais le mouvement montre moins de puissance. La prochaine résistance est à 243,70 CHF. La rupture du support à 206,50 CHF invaliderait cette tendance.

Valérie GASTALDY

Short term view - ROCHE HOLDING AG : Prices are still making progress

The background trend is clearly bullish. Prices are still making progress but there is less power in the movement. The next resistance is at CHF 243.70. Breaking below the support at CHF 206.50 would invalidate the trend.

Valérie GASTALDY

Analyse court terme - ROCHE HOLDING AG : Les cours progressent encore.

La tendance de fond est clairement orientée à la hausse. Les cours progressent encore, mais le mouvement montre moins de puissance. La prochaine résistance est à 243,70 CHF. La rupture du support à 206,50 CHF invaliderait cette tendance.

Valérie GASTALDY

Short term view - ROCHE HOLDING AG : Prices are still making progress

The background trend is clearly bullish. Prices are still making progress but there is less power in the movement. The next resistance is at CHF 243.70. Breaking below the support at CHF 206.50 would invalidate the trend.

Valérie GASTALDY

Medium term view - ROCHE HOLDING AG : The recent fall is getting more vigorous.

The trend is bullish. The recent fall is getting more vigorous. The next support is at CHF 203.60. A break below CHF 203.60 would challenge the trend.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch